Search by Drug Name or NDC
NDC 00078-0734-61 Ilaris 150 mg/mL Details
Ilaris 150 mg/mL
Ilaris is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is CANAKINUMAB.
MedlinePlus Drug Summary
Canakinumab injection is used to treat certain periodic fever syndromes (inherited conditions in which the body attacks its own tissues and organs causing fever, inflammation, joint and muscle pain, eye redness or pain, stomach pain, rash, and fatigue) including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD)/ hyperimmunoglobulin D syndrome (HIDS), and familial Mediterranean fever (FMF) in adults and children. Canakinumab injection is also used to treat Still's disease (a condition in which the body attacks its own tissues causing inflammation, fever, rash, headache, fatigue, and joint and muscle pain), including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age or older. Canakinumab is in a class of medications called interleukin antagonists. It works by blocking the activity of interleukin, a substance in the body that causes inflammation.
Related Packages: 00078-0734-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Canakinumab Injection
Product Information
| NDC | 00078-0734 |
|---|---|
| Product ID | 0078-0734_05e186cc-0727-4347-abe9-a768f526d562 |
| Associated GPIs | 66460020002015 |
| GCN Sequence Number | 077202 |
| GCN Sequence Number Description | canakinumab/PF VIAL 150 MG/ML SUBCUT |
| HIC3 | S2V |
| HIC3 Description | ANTI-INFLAMMATORY, INTERLEUKIN-1 BETA BLOCKERS |
| GCN | 43148 |
| HICL Sequence Number | 036497 |
| HICL Sequence Number Description | CANAKINUMAB/PF |
| Brand/Generic | Brand |
| Proprietary Name | Ilaris |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | canakinumab |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/mL |
| Substance Name | CANAKINUMAB |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125319 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0734-61 (00078073461)
| NDC Package Code | 0078-0734-61 |
|---|---|
| Billing NDC | 00078073461 |
| Package | 1 VIAL, SINGLE-USE in 1 CARTON (0078-0734-61) / 1 mL in 1 VIAL, SINGLE-USE |
| Marketing Start Date | 2016-12-22 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |